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CLINICAL PERSPECTIVE ON THE ROLE OF BIOMARKERS
IN THE DIAGNOSIS AND MONITORING OF
OSTEOARTHRITIS
V. Byers-Kraus
Duke Univ., Durham, NC
Purpose: Evaluating the clinical effectiveness of drugs for OA
poses special challenges because of the difﬁculty in assessing the
stage and state of the disease, the slow changes in the current
radiographic measure of joint space narrowing, and the duration of
the studies necessary to show signiﬁcant effects. Biomarkers are
a potential means of providing quantitative and objective indices
to help overcome some of these challenges.
Methods: Before a biomarker is eventually adopted as a clinical
tool, it requires biological and clinical validation, ideally in large
numbers of patient samples. The evidentiary process linking a
biomarker with biology and clinical end points has recently been
deﬁned as biomarker qualiﬁcation.
Results: Although the qualiﬁcation of OA biomarkers is gaining
momentum, the current state of biomarkers for OA is analogous
to the state of biomarkers for osteoporosis 30 years ago. Unlike
osteoporosis, for which bone density emerged as the gold standard
measure, in OA it remains to be determined what surveillance
measures will ultimately be adopted. Like osteoporosis, OA has a
silent molecular stage, and late stage adverse outcomes. OA has
added complexity and heterogeneity with different patterns of joint
involvement and different inciting pathologies including genetics,
injury, and joint anatomy to name a few.
Conclusions: Increasingly, studies are demonstrating biomarkers
with the ability to quantify various dimensions of the OA process
with accuracy and precision. Biomarkers used singly and in com-
bination, in conjunction with imaging, demographics, and OA risk
factors, provide a rich toolset for evaluating the efﬁcacy of drugs
for OA. Increasing use and reliance on a comprehensive toolset, it
is hoped, will contribute substantially to development and approval
of therapeutics to favorably impact the course of this disease.
I-2
IMMUNOHISTOCHEMISTRY AND CONFOCAL TECHNIQUES
C.M. Brown
McGill Univ. Imaging Facility, Monteal, QC, Canada
Purpose: To provide an introduction to Immunohistochemistry and
Confocal Imaging Techniques
Methods: How to perform imaging of immunohistochemistry sam-
ples either with a colour camera or blue, green and red ﬁlter sets.
How to generate high quality confocal images and to separate
ﬂuorescence dyes with similar ﬂuorescence spectra. How to re-
move specimen auto-ﬂuorescence from the signal from speciﬁc
ﬂuorescence probes.
Results: Proper camera colour balance is required to gener-
ate suitable images of immunohistological samples. Three im-
ages using blue, green and red ﬁlters can be generated using a
monochrome camera and overlayed in image processing software
in order to image Immunohistological samples without the need
for a colour camera. With the proper imaging settings high qual-
ity confocal images can be generated from ﬂuorescent samples.
Spectral imaging can be used to separate dyes of similar colour
and to remove specimen auto-ﬂuorescence.
Conclusions: Following this presentation attendees should have
a clear idea of the main aspects to keep in mind when performing
brightﬁeld or confocal imaging.
I-3
STRATEGIES TO USE MODERN IMAGING TECHNOLOGIES
TO EVALUATE PATIENTS WITH OA
F.M. Cicuttini
Monash Univ., Melbourne, Australia
Purpose: The radiographic examination of joints is useful in the di-
agnosis of osteoarthritis (OA) and has enabled signiﬁcant progress
to be made in our understanding of risk factors for OA. However
new imaging modalities provide novel opportunities to investigate
the pathogenesis of OA through examining the whole joint. The
aim of this presentation is to examine current strategies using
modern imaging technologies in the evaluation of patients with OA
and to consider the potential impact of these new approaches.
OA is a disease of the whole joint. By using improved, non-invasive
techniques such as magnetic resonance imaging (MRI) to visu-
alise the whole joint, it is now possible to examine the relative
role of different joint structures such as cartilage, bone, menisci,
synovium and ligaments simultaneously on the symptomatology
and progression of OA. Recent work demonstrates that knee OA is
the result of multiple, cumulative changes in joint structure occur-
ring in the apparently healthy, asymptomatic state, which progress
until clinical disease presents itself. The use of MRI, a sensitive
and non-invasive tool, has enabled the examination of these early
changes of OA, prior to radiographic disease, through to the joint
with end stage disease. This shows that our current deﬁnitions of
radiographic tibiofemoral OA fall on the continuum from health to
disease, with approximately 10% of articular knee cartilage lost
before radiological disease is detected. Since OA is recognised
as a multifactorial disease, using a sensitive examination of joint
structure, provides opportunities to examine new hypotheses in
the pathogenesis of OA. Identifying early changes may provide
novel targets for the prevention and treatment of knee OA. At
an individual level, they may also help identify those at risk of
OA who may beneﬁt from early lifestyle modiﬁcation. Although
much of the current wok has focussed on MRI, other modalities
such as ultrasound, scintigraphy, and CT are also being used in
the evaluation of patients with OA and provide complementary
information.
I-4
NEW APPROACHES TO MEASUREMENT OF OUTCOMES
TO ASSESS EFFICACY OF OSTEOARTHRITIS TREATMENT:
THE OARSI-OMERACT INITIATIVE
M. Dougados
René Descartes Univ., Paris, France
Purpose: In order to propose a set of criteria for considering
total articular replacement (e.g. medical treatment failure) to be
used as an end-point in clinical trials evaluating potential disease
modifying drugs, a joint OARSI-OMERACT initiative is aiming at
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proposing a deﬁnition of structural progression and a deﬁnition of
unacceptable symptom state.
Methods: The group in charge of the “unacceptable symptom
state” ﬁrst decided to focus on 2 domains e.g. pain and functional
impairment, second to propose new tools for evaluating such
domains, and third to conduct a cross sectional study in order to
propose a threshold of the value in such tools above which the
level of symptoms will be considered as not acceptable. For such
purpose, the opinion of the orthopedists concerning their visiting
patients (e.g. good candidate for total articular replacement yes/no)
was considered as the gold standard.
Results: An OARSI-OMERACT pain tool and an OARSI-
OMERACT function hip/knee tools have been elaborated [1–3].
The study aimed at proposing a threshold in such tools for deﬁn-
ing a non acceptable symptom state has recruited more than 2000
patients in more than 10 different countries.
Conclusions: Such joint OARSI-OMERACT initiative should facil-
itate the conduct of clinical trials to more accurately evaluate not
only symptomatic but also disease modifying treatments.
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I-5
ADVANCES IN THE UNDERSTANDING OF THE ROLE OF
AGING IN THE DEVELOPMENT AND PROGRESSION OF OA
J. Haag
Inst. fuer Pathologie, Leipzig, Germany
The prevalence of primary osteoarthritis (OA) increases with age.
Aging, therefore, represents a major risk factor for OA. Cartilage
degradation is most certainly not simply an effect of wear and
tear processes but is signiﬁcantly inﬂuenced by molecular reg-
ulatory systems. However, the degree to which regulated aging
processes are responsible for the loss of tissue function in OA is
not yet fully resolved. Several experimental ﬁndings are consistent
with a senescent-like state of arthritic chondrocytes and cartilage.
These include a shortening of the telomere ends, the expression
of senescence markers like SA-βgal, altered cytokine expression
proﬁles and age-dependent modiﬁcations of the extracellular ma-
trix. Our own results show an increased transcriptional noise and
elevated DNA damage levels in OA chondrocytes.
The process of aging is not an unregulated process but is
regulated by evolutionary conserved pathways that safeguard
the maintenance of cellular homeostasis. The deregulation of
these regulatory networks is linked to the development of aging-
associated diseases. In this respect, perturbations of the so-
matotrophic axis (GH-IGF-Akt) are of special interest. Mice with
reduced IGF-1 and insulin signaling (Ames and Snell dwarf mice,
Klotho-overexpressing mice) live signiﬁcantly longer than littermate
mice and show an overall reduction of aging-related pathological
changes. Interestingly, long-lived Snell dwarfs (which do not pro-
duce growth hormone) show a delay of articular cartilage aging
and do not develop OA at an age when up to 58% of their wild-type
littermates already do.
Our own research provides evidence for a major perturbation of
the IGF-Akt-FoxO signaling pathway in human osteoarthritic knee
cartilage with reduced FoxO expression levels and an overall
reduction of the expression of important stress-response genes
concomitant with higher cellular damage levels. The transcript
levels of all four known FoxO genes, FoxO1, FoxO3a, FoxO4
and FoxO6 were signiﬁcantly reduced in the osteoarthritic tissue.
This decrease was more pronounced in late osteoarthritic carti-
lage compared with early degenerated tissues. Several important
FoxO target genes were substantially deregulated. The cell cycle
regulators p21, p27 and cyclin G2 were signiﬁcantly downregu-
lated, while cyclin D1 was markedly upregulated, corresponding
to the downregulation of FoxO levels. The FoxO regulated genes
involved in oxidative defense also showed differential regulation.
The expression of SOD genes was substantially reduced in OA,
with SOD2 showing the most substantial decline. mRNA levels of
GADD45, a gene involved in DNA repair, were markedly lower in
osteoarthritic tissue.
The emerging insights into the mechanisms underying general ag-
ing processes promise to open up new avenues for drug discovery.
The identiﬁcation of pharmacologically tractable drug targets within
these conserved aging pathways will make it possible to develop
novel therapeutic options for age-related diseases, including pri-
mary osteoarthritis. We expect, therefore, that further insights on
the role of natural aging processes in the development and pro-
gression of primary osteoarthritis, and thus a better understanding
of the processes underlying cartilage aging and degradation, will
translate into novel ideas and ways of preventing and treating OA.
I-6
BASIC PERSPECTIVE ON THE ROLE OF BIOMARKERS IN
THE DIAGNOSIS AND MONITORING OF OSTEOARTHRITIS
D. Heinegård
Lund Univ., Lund, Sweden
An opportunity to detect early stages of process leading to clinical
osteoarthritis (OA) is offered by the emerging molecular marker
technology. This development will be further advanced when mark-
ers with spatial, temporal and process speciﬁcity become available.
Molecular markers have the potential to provide information the
relative activity of the process of degradation and repair attempts,
including an inadequate tuning of the synthesis of new constituents
of the matrix.
markers with apparent tissue speciﬁcity: There are a number of
molecules that are released from cartilage as a result of the local
process. These include aggrecan, where the fragments containing
the chondroitin sulfate chains appear early in disease and are
formed also in the normal tissue turnover. The ﬁne structure of
the glycosaminoglycan side chains change both with age and in
disease.
The G1 hyaluronan binding domain is initially retained in the tissue
bound to hyaluronan to be released in late stage tissue injury.
Cleavage of Aggrecan at several speciﬁc sites by ADAMTS-family
members provides unique cleavage sites and neo-epitope anti-
bodies only recognizing fragments with an end corresponding the
cleavage are available and applied to studies of joint disease.
Collagen type II epitopes studied include those of the telopeptides
at the ends of the molecule and those from cleavages of the
triple helical region. Applications of these assays demonstrate
increased release of fragmented collagen in osteoarthritis. There
are discussions on the speciﬁcity of some of these assays.
New synthesis of collagen can be detected by the production and
release of the propeptides cleaved of the precursor procollagen II.
Such assays have been employed in studies of collagen synthesis
in joint disease.
Spatial speciﬁcity is possible to obtain by using proteins which are
present in only a given tissue compartment.
Interterritorial distribution: Examples of such proteins are CILP
and COMP. Both occur preferentially in the interterritorial matrix
of the adult articular cartilage.
COMP is released at an early stage of joint disease. Accordingly
elevated COMP levels may serve as a predictor of destruction of
the cartilage identiﬁed by imaging years later. One shortcoming
of many of currently employed assays, including for COMP, is
the background provided by turnover in normal cartilages. As a
